Clinical Trial Update: Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167 [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating various modified-release tablet formulations of Lu AF11167; the trial has completed in participants with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Lu AF11167

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED